Formulation Development
BiomX Announces Positive Topline Results From Part 2 of the Phase 1b/2a Trial Evaluating Treatment for Chronic Pulmonary Infections in Patients With Cystic Fibrosis
BiomX Inc. recently announced positive safety and efficacy results from Part 2 of the Phase 1b/2a trial evaluating the company’s novel phage cocktail, BX004, for…
Oxford BioTherapeutics Announces Partner Boehringer Ingelheim Received Fast Track Designation for BI 764532 for the Potential Treatment of Advanced or Metastatic Large-Cell Neuroendocrine Carcinoma of the Lung
Oxford BioTherapeutics recently announced the US FDA has granted Fast Track designation to BI 764532 for the potential treatment of advanced or metastatic large-cell neuroendocrine carcinoma of….
Dyadic Announces Top-Line Results From its Successful Phase 1 Clinical Trial for a First-in-Human Filamentous Fungal-Based Vaccine Candidate
Dyadic International, Inc. recently announced successful top-line results for the Phase 1 clinical trial of its recombinant protein RBD vaccine candidate, DYAI-100. This marks the…
Lumen Bioscience Announces $5.5-Million Funding to Support New Research Program for Mucosal Vaccine Platform Technology
Lumen Bioscience recently announced $5.5 million in new funding from the US Department of Defense, operating through the Medical CBRN Defense Consortium (MCDC), to develop…
Roivant Announces Positive IMVT-1402 Initial 600-mg MAD Results That Confirm Best-in-Class Potential
Immunovant, Inc. recently announced initial data from 600-mg MAD cohort of a Phase 1 clinical trial of IMVT-1402 in healthy adults. The results show that…
Avidity Biosciences Announces Expansion of Cardiovascular Collaboration With Bristol Myers Squibb
Global licensing and research collaboration to focus on discovery, development and commercialization of up to five cardiovascular targets leveraging Avidity’s proprietary AOC platform technology….
Evaxion to Unveil Potentially Groundbreaking AI-Immunology Precision Cancer Vaccine Concept
Evaxion Biotech A/S recently announced the presentation of its novel precision vaccine concept at the 65th American Society of Hematology (ASH) Annual Meeting, taking place…
WEBINAR - 2024 Trends in Topical Drug Delivery: Insights & Innovation
This webinar will discuss some of the key trends from these leaders in the topical market on both a global and regional level, including the increased importance of sensory properties and the rise in non-conventional product formats, among others…..
Roivant & Priovant Announce Results From Phase 2 Study of Oral Brepocitinib in Systemic Lupus Erythematosus
Roivant and Priovant recently announced the Phase 2 study evaluating oral brepocitinib in adult patients with moderate to severe active lupus did not meet its…
GRI Bio Announces FDA Clearance of IND for Lead Program GRI-0621, a Type 1 Invariant NKT Antagonist for the Treatment of Idiopathic Pulmonary Fibrosis
GRI Bio, Inc. recently announced the US FDA has cleared the company’s Investigational New Drug (IND) application for GRI-0621 for the treatment of IPF. The…
Biodexa Enters Agreements to Acquire Exclusive Worldwide License to a Phase 2 Ready Asset for Type 1 Diabetes
Biodexa Pharmaceuticals PLC recently announced it has entered into an agreement for the assignment of Adhera Therapeutics, Inc.’s rights to tolimidone (formerly coded MLR-1023) under an exclusive,….
ADvantage Therapeutics Commences Enrollment for Phase 2b Clinical Trial for Alzheimer’s Disease Treatment
ADvantage Therapeutics, Inc. recently announced the first patient enrolled in the company’s European Phase 2b clinical trial on its lead candidate AD04 for the treatment…
Alladapt Immunotherapeutics Receives FDA Fast Track Designation for the Treatment of Mono- and Multi-Food Allergies
Alladapt Immunotherapeutics, Inc. recently announced that ADP101, its investigational multi-food oral immunotherapy (mOIT) designed to simultaneously treat allergy to one or more of the world’s…
Aerovate Therapeutics Announces Simultaneous Completion of Enrollment in Phase 2b Portion & Enrollment of First Patient Into Phase 3 Trial Evaluating AV-101 for the Treatment of Pulmonary Arterial Hypertension
Aerovate Therapeutics, Inc. recently announced the Phase 2b portion of the Inhaled iMatinib Pulmonary Arterial Hypertension Clinical Trial (IMPAHCT) Phase 2b/Phase 3 study evaluating AV-101,…
Zevra Therapeutics Completes Acquisition of Acer Therapeutics in its Journey to Become a Leading Rare Disease Company
Zevra Therapeutics, Inc. recently announced the completion of its acquisition of Acer Therapeutics Inc., which marks a significant step forward in executing Zevra’s strategy to become….
Hovione Acquires ExtremoChem & Its Portfolio of Proprietary Sugars to Support Customers With Stabilization & Delivery of Biopharmaceuticals
Hovione, the specialist integrated CDMO and the leader in spray drying and particle engineering, has recently announced it has acquired ExtremoChem Lda (ExtremoChem), an innovative start-up company focused on….
Anavex Initiates Regulatory Submission of Oral Blarcamesine for Alzheimer’s Disease to EMA
Anavex Life Sciences Corp. recently announced representatives of Anavex met with team members of the European Medicines Agency (EMA). These meetings discussed the debilitating pathology…
Yamo Pharmaceuticals Enrolls Final Patient in Phase 2 Study Evaluating L1-79 to Treat the Core Symptoms of Autism Spectrum Disorder
Yamo Pharmaceuticals LLC recently announced it has completed enrollment in its Phase 2 study evaluating L1-79 in adolescents and young adults with autism spectrum disorder…
Boehringer Ingelheim Expands Usage of Genedata Biologics to DMPK Operations
Genedata recently announced Boehringer Ingelheim has expanded usage of the Genedata platform to include the Drug Metabolism and Pharmacokinetics (DMPK) group in the US. The…
Medicenna Announces Compelling Survival Benefit From Phase 2b Study of Bizaxofusp in Recurrent Gliobastoma
Medicenna Therapeutics Corp. recently announced a poster presentation and an oral summary highlighting longer term follow up results from the Phase 2b clinical trial of…
